share_log

藥明生物:董事會會議日期

WUXI BIO: DATE OF BOARD MEETING

香港交易所 ·  Feb 14 03:45
Summary by Moomoo AI
藥明生物技術有限公司宣佈將於2024年3月26日(星期二)舉行董事會會議,目的是考慮及通過集團截至2023年12月31日止年度的全年業績及其刊發。該會議將由董事長李革博士主持,並有執行董事陳智勝博士及周偉昌博士,非執行董事李革博士、吳亦兵博士及曹彥凌先生,以及獨立非執行董事William Robert Keller先生、Kenneth Walton Hitchner III先生、戴國良先生及陳珏博士出席。會議的主要議程為審核及批准公司全年業績報告。
藥明生物技術有限公司宣佈將於2024年3月26日(星期二)舉行董事會會議,目的是考慮及通過集團截至2023年12月31日止年度的全年業績及其刊發。該會議將由董事長李革博士主持,並有執行董事陳智勝博士及周偉昌博士,非執行董事李革博士、吳亦兵博士及曹彥凌先生,以及獨立非執行董事William Robert Keller先生、Kenneth Walton Hitchner III先生、戴國良先生及陳珏博士出席。會議的主要議程為審核及批准公司全年業績報告。
Pharmaceutical Biotechnology Limited announced that a Board Meeting will be held on 26 March 2024 (Tuesday) to consider and approve the Group's annual results for the year ended 31 December 2023 and their publication. The meeting will be chaired by Dr. Li Keung, Chairman, and attended by Executive Directors Dr. Chan Chi Shing and Dr. Zhou Wai Cheong, Non-Executive Directors Dr. Li Keung, Dr. Wu Yibing and Mr. Cao Yen-ling, as well as Independent Non-Executive Directors Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Dai Kwok Leung and Dr. Chan. The main agenda of the meeting is to review and approve the company's annual results report.
Pharmaceutical Biotechnology Limited announced that a Board Meeting will be held on 26 March 2024 (Tuesday) to consider and approve the Group's annual results for the year ended 31 December 2023 and their publication. The meeting will be chaired by Dr. Li Keung, Chairman, and attended by Executive Directors Dr. Chan Chi Shing and Dr. Zhou Wai Cheong, Non-Executive Directors Dr. Li Keung, Dr. Wu Yibing and Mr. Cao Yen-ling, as well as Independent Non-Executive Directors Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Dai Kwok Leung and Dr. Chan. The main agenda of the meeting is to review and approve the company's annual results report.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more